# Efficacy and Tolerability of an Intra-Nasal Testosterone Product

> **NCT00975650** · PHASE2 · COMPLETED · sponsor: **Acerus Pharmaceuticals Corporation** · enrollment: 57 (actual)

## Conditions studied

- Hypogonadism

## Interventions

- **DRUG:** Nasobol®
- **DRUG:** Androderm® (Positive Control)

## Key facts

- **NCT ID:** NCT00975650
- **Lead sponsor:** Acerus Pharmaceuticals Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08
- **Primary completion:** 2010-05
- **Final completion:** 2010-05
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2018-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00975650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00975650, "Efficacy and Tolerability of an Intra-Nasal Testosterone Product". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00975650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*